Why Novo Nordisk Stock Slumped on Monday

Key Points An analyst downgraded his recommendation on the Danish pharmaceutical's equity. He changed it from the equivalent of hold to buy. 10 stocks we like better than Novo Nordisk › Drug tariffs, tough competition, and a fresh analyst recommendation downgrade were the burdens pulling down Novo Nordisk (NYSE: NVO) stock on Monday. In some respects, then, it was surprising that the company's shares didn't do worse than the 0.2% slump they were hit with across that trading session. Meanwhile, the ...